98 related articles for article (PubMed ID: 11055798)
1. Intratumoral IL-12 gene transfer improves the therapeutic efficacy of IL-12 but not IL-19.
Sobota V; Bubeník J; Símová J; Jandlová T
Folia Biol (Praha); 2000; 46(5):191-3. PubMed ID: 11055798
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cell vaccine therapy by immunization with fusion cells of interleukin-2 gene-transduced, spleen-derived dendritic cells and tumour cells.
Ogawa F; Iinuma H; Okinaga K
Scand J Immunol; 2004 May; 59(5):432-9. PubMed ID: 15140052
[TBL] [Abstract][Full Text] [Related]
3. Systemic administration of rIL-12 synergistically enhances the therapeutic effect of a TNF gene-transduced cancer vaccine.
Taniguchi F; Yamagishi H; Fujiwara H; Ueda Y; Fuji N; Yoshimura T; Oka T
Gene Ther; 1998 Dec; 5(12):1677-84. PubMed ID: 10023447
[TBL] [Abstract][Full Text] [Related]
4. Granulocyte-macrophage colony-stimulating factor-producing tumour vaccines.
Rössner P; Bubeník J; Sobota V; Indrová M; Hájková R; Mendoza L; Jandlová T; Símová J
Folia Biol (Praha); 1999; 45(5):173-7. PubMed ID: 10730885
[TBL] [Abstract][Full Text] [Related]
5. IL-2 gene-modified tumour vaccines: monitoring of IL-2 levels in serum and peritoneal cavity of vaccinated mice.
Indrová M; Pajtasz-Piasecka E; Jandlová T; Símová J; Bubeník J; Radzikowski C
Folia Biol (Praha); 1999; 45(1):7-11. PubMed ID: 10732712
[TBL] [Abstract][Full Text] [Related]
6. Melanoma differentiation-associated gene-7 (mda-7)/interleukin (IL)-24 induces anticancer immunity in a syngeneic murine model.
Miyahara R; Banerjee S; Kawano K; Efferson C; Tsuda N; Miyahara Y; Ioannides CG; Chada S; Ramesh R
Cancer Gene Ther; 2006 Aug; 13(8):753-61. PubMed ID: 16543916
[TBL] [Abstract][Full Text] [Related]
7. Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF.
Mikysková R; Indrová M; Símová J; Jandlová T; Bieblová J; Jinoch P; Bubeník J; Vonka V
Int J Oncol; 2004 Jan; 24(1):161-7. PubMed ID: 14654953
[TBL] [Abstract][Full Text] [Related]
8. Genetic modification of a murine fibrosarcoma to produce interleukin 7 stimulates host cell infiltration and tumor immunity.
McBride WH; Thacker JD; Comora S; Economou JS; Kelley D; Hogge D; Dubinett SM; Dougherty GJ
Cancer Res; 1992 Jul; 52(14):3931-7. PubMed ID: 1617669
[TBL] [Abstract][Full Text] [Related]
9. Gene therapy of plasmacytoma: comparison of the therapeutic efficacy of tumour cells transduced with the interleukin-2, interleukin-4, or interleukin-6 genes.
Bubeník J; Símová J; Zeuthen J; Diamant M; Jandlová T; Bubeníková D
Folia Biol (Praha); 1994; 40(1-2):29-36. PubMed ID: 7958062
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral IL-18 gene transfer improves therapeutic efficacy of antibody-targeted superantigen in established murine melanoma.
Wang Q; Yu H; Ju DW; He L; Pan JP; Xia DJ; Zhang LH; Cao X
Gene Ther; 2001 Apr; 8(7):542-50. PubMed ID: 11319621
[TBL] [Abstract][Full Text] [Related]
11. Recombinant interleukin-2 acts as an adjuvant and helps to increase the efficacy of tumour vaccines.
Vondrys P; Símová J; Takácová S; Jandlová T; Bubeník J
Folia Biol (Praha); 1997; 43(1):39-40. PubMed ID: 9158948
[TBL] [Abstract][Full Text] [Related]
12. Effects of combined therapy with interleukin 2 and interleukin 12 gene-transfected tumor vaccine for head and neck carcinoma.
Kimura Y; Mizuno H; Satake K; Tahara H; Tsukuda M
Arch Otolaryngol Head Neck Surg; 2003 Nov; 129(11):1181-5. PubMed ID: 14623747
[TBL] [Abstract][Full Text] [Related]
13. Insertion of the IL-2 gene decreases tumorigenicity of murine fibrosarcoma.
Kuśnierczyk H; Załecki P; Pajtasz-Piasecka E; Radzikowski C
Arch Immunol Ther Exp (Warsz); 1998; 46(4):259-65. PubMed ID: 9779293
[TBL] [Abstract][Full Text] [Related]
14. Adenovirus vector-mediated overexpression of a truncated form of the p65 nuclear factor kappa B cDNA in dendritic cells enhances their function resulting in immune-mediated suppression of preexisting murine tumors.
Lee JM; Mahtabifard A; Yamada R; Crystal RG; Korst RJ
Clin Cancer Res; 2002 Nov; 8(11):3561-9. PubMed ID: 12429647
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-3 in gene therapy of cancer.
McBride WH; Dougherty GD; Wallis AE; Economou JS; Chiang CS
Folia Biol (Praha); 1994; 40(1-2):62-73. PubMed ID: 7958065
[TBL] [Abstract][Full Text] [Related]
16. Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
Indrová M; Bubeník J; Mikysková R; Mendoza L; Símová J; Bieblová J; Jandlová T; Jinoch P; Smahel M; Vonka V; Pajtasz-Piasecka E
Int J Oncol; 2003 Mar; 22(3):691-5. PubMed ID: 12579325
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic and specific antitumor immunity induced by co-administration of immature dendritic cells and adenoviral vector expressing biologically active IL-18.
Tanaka F; Hashimoto W; Robbins PD; Lotze MT; Tahara H
Gene Ther; 2002 Nov; 9(21):1480-6. PubMed ID: 12378411
[TBL] [Abstract][Full Text] [Related]
18. Successful immunogene therapy using colon cancer cells (colon 26) transfected with plasmid vector containing mature interleukin-18 cDNA and the Igkappa leader sequence.
Yoshimura K; Hazama S; Iizuka N; Yoshino S; Yamamoto K; Muraguchi M; Ohmoto Y; Noma T; Oka M
Cancer Gene Ther; 2001 Jan; 8(1):9-16. PubMed ID: 11219497
[TBL] [Abstract][Full Text] [Related]
19. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
20. Adenovirus-mediated interleukin-18 mutant in vivo gene transfer inhibits tumor growth through the induction of T cell immunity and activation of natural killer cell cytotoxicity.
Hwang KS; Cho WK; Yoo J; Seong YR; Kim BK; Kim S; Im DS
Cancer Gene Ther; 2004 Jun; 11(6):397-407. PubMed ID: 15044962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
